中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
5期
609-611
,共3页
程江涛%朱初麟%校卫东%陈鹏%胡宇才%牛琳琳%杜廷海%王永霞
程江濤%硃初麟%校衛東%陳鵬%鬍宇纔%牛琳琳%杜廷海%王永霞
정강도%주초린%교위동%진붕%호우재%우림림%두정해%왕영하
经皮冠状动脉介入术%曲美他嗪%心肌损伤%炎症因子
經皮冠狀動脈介入術%麯美他嗪%心肌損傷%炎癥因子
경피관상동맥개입술%곡미타진%심기손상%염증인자
Percutaneous coronary intervention%Trimetazidine%Myocardial injury%Inflammatory cytokines
目的 观察曲美他嗪对经皮冠状动脉介入术(PCI)相关心肌损伤的影响.方法 入选拟行PCI的不稳定型心绞痛患者80例,采用随机数字表法分为曲美他嗪组和对照组,各40例,所有入选患者均服用阿司匹林、氯吡格雷及常规药物治疗,曲美他嗪组PCI术前3d开始口服曲美他嗪,20 mg/次,3次/d,直至采血结束;于PCI术前及术后6、24 h采血测定血清肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、C反应蛋白(CRP)的浓度,另测定术前及术后6h白细胞介素6(IL-6)的浓度.结果 术前2组患者各项指标差异均无统计学意义(P＞0.05).曲美他嗪组PCI术后在各个测量时点的cTnI、CK-MB、CRP、IL-6均明显低于对照组[术后6 h:cTnI为(0.52 ±0.22) μg/L比(1.96-1.08) μg/L、CK-MB为(52±13) U/L比(89±19)U/L、CRP为(9.6±2.8) mg/L比(12.7±2.5) mg/L、IL-6为(23±6) ng/L比(32±6)ng/L;术后24h:cTnI为(0.44±0.26) μg/L比(1.98±1.12) μg/L、CK-MB为(43±10) U/L比(72±18) U/L、CRP为(14.8±5.6)mg/L比(23.2±7.2) mg/L] (P＜0.05).结论 曲美他嗪能明显降低PCI术后患者的心肌损伤标志物和炎性因子水平,减轻心肌损伤,对心肌有保护作用.
目的 觀察麯美他嗪對經皮冠狀動脈介入術(PCI)相關心肌損傷的影響.方法 入選擬行PCI的不穩定型心絞痛患者80例,採用隨機數字錶法分為麯美他嗪組和對照組,各40例,所有入選患者均服用阿司匹林、氯吡格雷及常規藥物治療,麯美他嗪組PCI術前3d開始口服麯美他嗪,20 mg/次,3次/d,直至採血結束;于PCI術前及術後6、24 h採血測定血清肌鈣蛋白I(cTnI)、肌痠激酶同工酶(CK-MB)、C反應蛋白(CRP)的濃度,另測定術前及術後6h白細胞介素6(IL-6)的濃度.結果 術前2組患者各項指標差異均無統計學意義(P＞0.05).麯美他嗪組PCI術後在各箇測量時點的cTnI、CK-MB、CRP、IL-6均明顯低于對照組[術後6 h:cTnI為(0.52 ±0.22) μg/L比(1.96-1.08) μg/L、CK-MB為(52±13) U/L比(89±19)U/L、CRP為(9.6±2.8) mg/L比(12.7±2.5) mg/L、IL-6為(23±6) ng/L比(32±6)ng/L;術後24h:cTnI為(0.44±0.26) μg/L比(1.98±1.12) μg/L、CK-MB為(43±10) U/L比(72±18) U/L、CRP為(14.8±5.6)mg/L比(23.2±7.2) mg/L] (P＜0.05).結論 麯美他嗪能明顯降低PCI術後患者的心肌損傷標誌物和炎性因子水平,減輕心肌損傷,對心肌有保護作用.
목적 관찰곡미타진대경피관상동맥개입술(PCI)상관심기손상적영향.방법 입선의행PCI적불은정형심교통환자80례,채용수궤수자표법분위곡미타진조화대조조,각40례,소유입선환자균복용아사필림、록필격뢰급상규약물치료,곡미타진조PCI술전3d개시구복곡미타진,20 mg/차,3차/d,직지채혈결속;우PCI술전급술후6、24 h채혈측정혈청기개단백I(cTnI)、기산격매동공매(CK-MB)、C반응단백(CRP)적농도,령측정술전급술후6h백세포개소6(IL-6)적농도.결과 술전2조환자각항지표차이균무통계학의의(P＞0.05).곡미타진조PCI술후재각개측량시점적cTnI、CK-MB、CRP、IL-6균명현저우대조조[술후6 h:cTnI위(0.52 ±0.22) μg/L비(1.96-1.08) μg/L、CK-MB위(52±13) U/L비(89±19)U/L、CRP위(9.6±2.8) mg/L비(12.7±2.5) mg/L、IL-6위(23±6) ng/L비(32±6)ng/L;술후24h:cTnI위(0.44±0.26) μg/L비(1.98±1.12) μg/L、CK-MB위(43±10) U/L비(72±18) U/L、CRP위(14.8±5.6)mg/L비(23.2±7.2) mg/L] (P＜0.05).결론 곡미타진능명현강저PCI술후환자적심기손상표지물화염성인자수평,감경심기손상,대심기유보호작용.
Objective To observe the protective effect of trimetazidine on myocardial injury induced by percutaneous coronary intervention (PCI).Methods Eighty patients with unstable angina were randomly divided into control group (n =40) and trimetazidine group (n =40).All patients were administrated with aspirin,clopidogrel and other medicines;the patients in trimetazidine group were additionally administrated with oral trimetazidine 3 days before PCI (20 mg/time,3 times/d) till the end of venous sampling.The levels of myocardial injury markers troponin I (cTnI),creatine kinase isoenzyme (CK-MB) and C-reactive protein (CRP) were measured before,6 and 24 h after PCI;the level of interleukin (IL) 6 was detected before and 6 h after PCI.Results There were no significant differences of all indexes between two groups before PCI (all P ＞ 0.05).The serum levels of cTnI,CK-MB,CRP 6 and 24 h after treatment and the level of IL-6 6 h after treatment in trimetazidine group was significantly decreased compared with those in control group [6 h after PCI:cTnI (0.52 ± 0.22) μg/L vs (1.96 ± 1.08) μg/L,CK-MB (52 ± 13) U/L vs (89 ± 19) U/L,CRP (9.6 ± 2.8) mg/L vs (12.7 ± 2.5) mg/L,IL-6 (23 ± 6) ng/L vs (32 ±6) ng/L;24 h after PCI:cTnI (0.44 ±0.26) μ g/L vs (1.98 ± 1.12) μg/L,CK-MB (43 ± 10) U/L vs (72 ± 18)U/L,CRP (14.8 ±5.6)mg/L vs (23.2 ±7.2)mg/L] (all P ＜0.05).Conclusion Trimetazidine can reduce the levels of myocardial injury markers and inflammatory cytokines after PCI and has myocardial protective effect.
